Ledger · 2026-09-05 · Advanced Materials / Aerospace Polymers

Solventless Eugenol-Furfurylamine Polybenzoxazine (E-F-Bz) via One-Pot Melt Condensation

Rejected

This concept did not clear the framework. The reasoning is published in full below.

What the assessment found

Incumbent benchmarkBismaleimide (BMI) Resin (Abron BR 720)
Entry applicationcomposite radomes and secondary hot-zone panels
Measured advantageNear-zero (~0.0%) volumetric shrinkage during cure versus 5.0%-10.0% for incumbent BMI resin (>5x step-change improvement / categorical reduction in residual stress)
Time to first revenue9 months
Gross margin at parity73.4%
Startup CapEx$124,000
Payback from first sale0.2 months
Capital productivity181.11x
Regulatory riskModerate — qualification costs reported ($120,000 estimated)
Market absenceVerified — the search is reported in the dossier: channels searched, companies searched, closest substitutes named
ProtectabilityOperational arbitrage — a viable business, but no protectable IP moat

Why it failed

Assessment

The proposal demonstrates high scientific rigor and commercial feasibility by translating a published bio-based polybenzoxazine synthesis into aerospace secondary composite structures. Unit economics show a 73.4% gross margin at price parity ($95/kg) with $124,000 startup CapEx and 9 months to first revenue. All gating criteria and voiding sub-tests are fully satisfied.

Also flagged

A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.


Assessed 2026-09-05 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts